Literature DB >> 11442565

Surveillance of antimicrobial resistance--what, how and whither?

R Bax1, R Bywater, G Cornaglia, H Goossens, P Hunter, V Isham, V Jarlier, R Jones, I Phillips, D Sahm, S Senn, M Struelens, D Taylor, A White.   

Abstract

OBJECTIVE: To express the views of a working party held to consider antibiotic resistance surveillance systems, their strengths and weaknesses, and their current and future applications.
METHODS: The participants, all of whom were experienced in this field, discussed the development of surveillance systems in relation to the increasing prevalence of resistance to antibacterial agents and the current interest in surveillance systems shown by many official bodies, in both the human and veterinary fields. The problems inherent in surveillance systems were considered together with the applications of different systems.
RESULTS: The properties of good antibiotic resistance surveillance systems were defined. Surveillance systems vary widely from those with a narrow base, focusing on few organisms in one disease area, to those covering many diseases, many organisms (including normal flora) and many compounds. Whatever their design, they should be able to detect significant differences and shifts in susceptibility to various antibacterial agents, and the information derived from them should reach as many interested parties as possible in a timely manner. In using this information to decide strategies, criteria for action need to be determined by pragmatic consensus. Funding remains a major problem, with few large studies being supported by official bodies in spite of their professed enthusiasm for surveillance. In consequence, many current systems are funded by the pharmaceutical industry and are of necessity restricted in their focus.
CONCLUSIONS: Antibiotic resistance surveillance studies should and can be well planned and well executed. Many current systems suffer from well-recognized but uncorrected biases. Consortium funding will be necessary for large schemes to be successful. There is no "ideal" surveillance system.

Entities:  

Mesh:

Year:  2001        PMID: 11442565     DOI: 10.1046/j.1198-743x.2001.00239.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  28 in total

1.  Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.

Authors:  D J Hoban; S K Bouchillon; J L Johnson; G G Zhanel; D L Butler; K A Saunders; L A Miller; J A Poupard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-28       Impact factor: 3.267

Review 2.  Reality of developing a community-wide antibiogram.

Authors:  Diane C Halstead; Noel Gomez; Yvette S McCarter
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals.

Authors:  F Luzzaro; E F Viganò; D Fossati; A Grossi; A Sala; C Sturla; M Saudelli; A Toniolo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-11       Impact factor: 3.267

4.  Antimicrobial Resistance of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System.

Authors:  Haley J Morrill; Jacob B Morton; Aisling R Caffrey; Lan Jiang; David Dosa; Leonard A Mermel; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  The Use of Antibiograms in Orthopedic Surgery.

Authors:  Scott R Nodzo; Nicholas B Frisch
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

6.  Antimicrobial resistance surveillance systems: Are potential biases taken into account?

Authors:  Olivia Rempel; Johann Dd Pitout; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

7.  Quantifying the associations between antibiotic exposure and resistance - a step towards personalised antibiograms.

Authors:  L Sanden; M Paul; L Leibovici; S Andreassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-26       Impact factor: 3.267

8.  Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.

Authors:  Kyungwon Lee; Mi Ae Lee; Chae Hoon Lee; Jongwook Lee; Kyoung Ho Roh; Sunjoo Kim; Jin Ju Kim; Eunmi Koh; Dongeun Yong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

9.  High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.

Authors:  Kyungwon Lee; Chang Hyun Lim; Ji Hyun Cho; Wee Gyo Lee; Young Uh; Hwi Jun Kim; Dongeun Yong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

10.  Increasing prevalence of vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aeruginosa in Korea: KONSAR study in 2001.

Authors:  Kyungwon Lee; Sook-Jin Jang; Hee-Joo Lee; Namhee Ryoo; Myungshin Kim; Seong-Geun Hong; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.